Recombinant adenovirus expressing hIFN-λ1 inhibits gastric adenocarcinoma cell line SGC-7901 proliferation

Bu,Xuefeng; Wang,Mubin; Zhang,Jie; Liu,Jun; Jia,Lijuan; Liang,Bing; Yan,Yulan

doi:10.3892/ol.2015.3890

Recombinant adenovirus expressing hIFN-λ1 inhibits gastric adenocarcinoma cell line SGC-7901 proliferation

Authors:
- Xuefeng Bu
- Mubin Wang
- Jie Zhang
- Jun Liu
- Lijuan Jia
- Bing Liang
- Yulan Yan
View Affiliations

Affiliations: Department of General Surgery, The Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu 212001, P.R. China, Department of Surgical Medicine, Clinical Medicine College of Jiangsu University, Zhenjiang, Jiangsu 212013, P.R. China, Department of Internal Medicine, Clinical Medicine College of Jiangsu University, Zhenjiang, Jiangsu 212013, P.R. China, Department of Respiratory Medicine, The Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu 212001, P.R. China
Published online on: November 6, 2015 https://doi.org/10.3892/ol.2015.3890
Pages: 287-292

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study is to investigate the effect of a recombinant plasmid adenovirus (pAd) expressing human interferon-λ1 (hIFN-λ1) on the proliferation of the gastric adenocarcinoma cell line SGC‑7901. For this purpose, human gastric adenocarcinoma SGC-7901 cells were infected with recombinant pAd-hIFN-λ1, pAd-LacZ and phosphate‑buffered saline (PBS), respectively, and the subsequent effects on the proliferation of the infected cells were compared. Cell proliferation was evaluated by MTT assay, while mRNA and protein expression of hIFN‑λ1 were detected by reverse transcription‑polymerase chain reaction analysis and immunofluorescence assay, respectively. In addition, terminal deoxynucleotidyl transferase deoxyuridine triphosphate nick end labeling assay and flow cytometry were conducted to analyze the rate of cell apoptosis. The results indicated that the proliferation of gastric adenocarcinoma SGC‑7901 cells was significantly inhibited by pAd‑hIFN‑λ1. Furthermore, the apoptosis rate and the mRNA and protein expression levels of hIFN‑λ1 were higher in pAd‑hIFN‑λ1‑transfected cells, compared with the pAd‑LacZ and PBS control groups. In conclusion, recombinant pAd‑hIFN‑λ1 induced the expression of hIFN‑λ1 in gastric adenocarcinoma SGC-7901 cells, and significantly inhibited cell proliferation by promoting apoptosis in these cancer cells.

View Figures

View References

1	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
2	Pourhoseingholi MA, Vahedi M and Baghestani AR: Burdenof gastrointestinal cancer in Asia; an overview. Gastroenterol Hepatol Bed Bench. 8:19–27. 2015.PubMed/NCBI
3	Tänzer M, Liebl M and Quante M: Molecular biomarkers in esophageal, gastric, and colorectal adenocarcinoma. Pharmacol Ther. 140:133–147. 2013. View Article : Google Scholar : PubMed/NCBI
4	Liang H and Kim YH: Identifying molecular drivers of gastric cancer through next-generation sequencing. Cancer Lett. 340:241–26. 2013. View Article : Google Scholar : PubMed/NCBI
5	González CA and Agudo A: Carcinogenesis, prevention and early detection of gastric cancer: Where we are and where we should go. Int J Cancer. 130:745–753. 2012. View Article : Google Scholar : PubMed/NCBI
6	Yared JA and Tkaczuk KH: Update on taxane development: New analogs and new formulations. Drug Des Devel Ther. 6:371–384. 2012.PubMed/NCBI
7	Bu XF, Zhang J, Jia LJ, Liang B, Zhang J, Liu Y and Yan YL: Effect of human interferon-λ1 recombinant adenovirus on a gastric cancer orthotopic transplantation model. Exp Ther Med. 8:1115–1122. 2014.PubMed/NCBI
8	Gao Z, Zhu M, Wu Y, Gao P, Qin Z and Wang H: Interferon-λ1 induces G1 phase cell cycle arrest and apoptosis in gastric carcinoma cells in vitro. Oncol Rep. 32:199–204. 2014.PubMed/NCBI
9	Ferrantini M, Capone I and Belardelli F: Interferon-α and cancer: Mechanisms of action and new perspectives of clinical use. Biochimie. 89:884–893. 2007. View Article : Google Scholar : PubMed/NCBI
10	Hui X, Chen H, Zhang S, Ma X, Wang X and Huang B: Antitumor activities of recombinant human interferon (IFN)-λ1 in vitro and in xenograft models in vivo for colon cancer. Cancer Lett. 311:141–151. 2011. View Article : Google Scholar : PubMed/NCBI
11	Yan Y, Zhang J, Liu Y, Zhu T, Yuan L, Ge Y, Ding H and Bu X: Inhibition of lung adenocarcinoma transfected with interleukin 28A recombinant adenovirus (Ad-mIFN-λ2) in vivo. Cancer Biother Radiopharm. 28:124–130. 2013. View Article : Google Scholar : PubMed/NCBI
12	Lopušná K, Režuchová I, Betáková T, et al: Interferons lambda, new cytokines with antiviral activity. Acta Virol. 57:171–179. 2013. View Article : Google Scholar : PubMed/NCBI
13	Steen HC and Gamero AM: Interferon-lambda as a potential therapeutic agent in cancer treatment. J Interferon Cytokine Res. 30:597–602. 2010. View Article : Google Scholar : PubMed/NCBI
14	Donnelly RP and Kotenko SV: Interferon-lambda: A new addition to an old family. J Interferon Cytokine Res. 30:555–564. 2010. View Article : Google Scholar : PubMed/NCBI
15	Meager A, Visvalingam K, Dilger P, Bryan D and Wadhwa M: Biological activity of interleukins −28 and −29: Comparison with type I interferons. Cytokine. 31:109–118. 2005. View Article : Google Scholar : PubMed/NCBI
16	Dumoutier L, Tounsi A, Michiels T, Sommereyns C, Kotenko SV and Renauld JC: Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-λ1: Similarities with type I interferon signaling. J Biol Chem. 279:32269–32274. 2004. View Article : Google Scholar : PubMed/NCBI
17	Lasfar A, Lewis-Antes A, Smirnov SV, Anantha S, Abushahba W, Tian B, Reuhl K, Dickensheets H, Sheikh F, Donnelly RP, et al: Characterization of the mouse IFN-lambdas ligand-receptor system: IFN-λs exhibit antitumor activity against B16 melanoma. Cancer Res. 66:4468–4477. 2006. View Article : Google Scholar : PubMed/NCBI
18	Khalighinejad N, Hariri H, Behnamfar O, Yousefi A and Momeni A: Adenoviral gene therapy in gastric cancer: A review. World J Gastroenterol. 14:180–184. 2008. View Article : Google Scholar : PubMed/NCBI
19	Rincon MY, VandenDriessche T and Chuah MK: Gene therapy for cardiovascular disease: Advances in vector development, targeting, and delivery for clinical translation. Cardiovasc Res. 108:4–20. 2015. View Article : Google Scholar : PubMed/NCBI
20	Wang I and Huang I: Adenovirus technology for gene manipulation and functional studies. Drug Discov Today. 5:10–16. 2000. View Article : Google Scholar : PubMed/NCBI
21	Büning H, Huber A, Zhang L, Meumann N and Hacker U: Engineering the AAV capsid to optimize vector-host-interactions. Curr Opin Pharmacol. 24:94–104. 2015. View Article : Google Scholar : PubMed/NCBI
22	Li Q, Kawamura K, Okamoto S, Fujie H, Numasaki M, Namba M, Nagata M, Shimada H, Kobayashi H and Tagawa M: Adenoviruses-mediated transduction of human oesophageal carcinoma cells with the interferon-λ genes produced anti-tumour effects. Br J Cancer. 105:1302–1312. 2011. View Article : Google Scholar : PubMed/NCBI
23	Kelly C, Klenerman P and Barnes E: Interferon-lambdas: The next cytokine storm. Gut. 60:1284–1293. 2011. View Article : Google Scholar : PubMed/NCBI
24	Tagawa M, Kawamura K, Li Q, Tada Y, Hiroshima K and Shimada H: A possible anticancer agent, type III interferon, activates cell death pathways and produces antitumor effects. Clin Dev Immunol. 2011:4790132011. View Article : Google Scholar : PubMed/NCBI
25	Sato A, Ohtsuki M, Hata M, Kobayashi E and Murakami T: Antitumor activity of IFN-λ in murine tumor models. J Immunol. 176:7686–7694. 2006. View Article : Google Scholar : PubMed/NCBI
26	Maher SG, Sheikh F, Scarzello AJ, Romero-Weaver AL, Baker DP, Donnelly RP and Gamero AM: IFNalpha and IFNlambda differ in their antiproliferative effects and duration of JAK/STAT signaling activity. Cancer Biol Ther. 7:1109–1115. 2008. View Article : Google Scholar : PubMed/NCBI
27	Li M, Liu X, Zhou Y and Su SB: Interferon-lambdas: The modulators of antivirus, antitumor, and immune responses. J Leukoc Biol. 86:23–32. 2009. View Article : Google Scholar : PubMed/NCBI
28	Li W, Lewis-Antes A, Huang J, Balan M and Kotenko SV: Regulation of apoptosis by type III interferons. Cell Prolif. 41:960–979. 2008. View Article : Google Scholar : PubMed/NCBI
29	Li Q, Kawamura K, Tada Y, Shimada H, Hiroshima K and Tagawa M: Novel type III interferons produce anti-tumor effects through multiple functions. Front Biosci (Landmark Ed). 18:909–918. 2013. View Article : Google Scholar : PubMed/NCBI
30	Woehlecke H, Pohl A, Alder-Baerens N, Lage H and Herrmann A: Enhanced exposure of phosphatidylserine in human gastric carcinoma cells overexpressing the half-size ABC transporter BCRP (ABCG2). Biochem J. 376:489–495. 2003. View Article : Google Scholar : PubMed/NCBI